Biomea Fusion, Inc.
No SEC Form 4 filings for $BMEA in the last 30 days.
See all $BMEA insider activity →Biomea Fusion (BMEA) stock rose 5.8% pre-market to $1.45 ahead of anticipated 28-day weight-reduction data from its Phase I GLP-131 trial, expected by Q3 2026. Recent positive developments include the first patient dosed in the OPAL study, analyst optimism, and better-than-expected Q2 earnings. The stock remains below its 52-week high of $2.99.
Biomea Fusion, Inc. (BMEA) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for the quarter calls for revenue of $0 and EPS of -$0.22 (USD).
Biomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001840439 0001840439 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
Over the past 7 days, alphai's AI scored 1 news story mentioning BMEA (Biomea Fusion, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BMEA coverage spans financial news, earnings and corporate actions.
Positive earnings surprise and imminent data catalyst likely support short‑term upside.
Ahead of the Aug 3 earnings release, the article provides consensus-style expectations (EPS -0.22, revenue 0) that can drive pre-earnings positioning and volatility.
Routine annual meeting voting results; no new operating, financial, or regulatory developments disclosed beyond governance outcomes.
Biotech company Biomea Fusion (BMEA) has received an optimistic initiation with a Buy rating and a significant price target from Rodman & Renshaw, indicating strong potential upside. The news suggests positive market sentiment towards BMEA based on clinical validation and upcoming trials.
Biomea Fusion's upcoming participation in Citi's biotech series is a positive signal, suggesting increased visibility and potential investor interest.
alphai scores every news story that mentions BMEA with an AI model for sentiment and relevance, and aggregates insider trades from Biomea Fusion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biomea Fusion (BMEA) stock rose 5.8% pre-market to $1.45 ahead of anticipated 28-day weight-reduction data from its Phase I GLP-131 trial, expected by Q3 2026. Recent positive developments include the first patient dosed in the OPAL study, analyst optimism, and better-than-expected Q2 earnings. The stock remains below its 52-week high of $2.99.
2 min readBiomea Fusion, Inc. (BMEA) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for the quarter calls for revenue of $0 and EPS of -$0.22 (USD).
1 min readBiomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001840439 0001840439 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readRodman & Renshaw has initiated coverage on Biomea Fusion Inc. (NASDAQ:BMEA) with a Buy rating and a price target of $8.00, suggesting over 500% potential upside. The firm believes Biomea's current valuation disconnects from its clinical progress, highlighting "early clinical validation of a genuine disease-modifying mechanism." This comes as Biomea plans Phase II trials for its diabetes drug, icovamenib, despite a recent downgrade from JPMorgan due to concerns regarding type 2 diabetes data.
3 min readSAN CARLOS, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( NASDAQ:BMEA ) , a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m.
2 min readSAN CARLOS, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( Nasdaq: BMEA ) , a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m.
2 min readBiomea Fusion Inc's ( NASDAQ:BMEA ) stock price plummeted after the company priced its public offering. The public offering includes 11.2 million shares of common stock and accompanying warrants to purchase an equal number of shares.
2 min readU.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.33% to 46,847.49 while the NASDAQ rose 0.11% to 22,967.90. The S&P 500 also rose, gaining, 0.15% to 6,750.64.
4 min readSAN CARLOS, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( NASDAQ:BMEA ) , a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase ...
2 min readSAN CARLOS, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( Nasdaq: BMEA ) , a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase ...
2 min read
